{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:21:33Z","timestamp":1793157693148,"version":"4.5.0"},"reference-count":37,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2018,1,25]],"date-time":"2018-01-25T00:00:00Z","timestamp":1516838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2018,2]]},"abstract":"ABSTRACT<\/jats:title>\n \n The\n in vitro<\/jats:italic>\n activity of the investigational siderophore cephalosporin, cefiderocol (formerly S-649266), was determined against a 2014\u20132016, 52-country, worldwide collection of clinical isolates of carbapenem-nonsusceptible\n Enterobacteriaceae<\/jats:named-content>\n (\n n<\/jats:italic>\n = 1,022), multidrug-resistant (MDR)\n Acinetobacter baumannii<\/jats:named-content>\n (\n n<\/jats:italic>\n = 368), MDR\n Pseudomonas aeruginosa<\/jats:named-content>\n (\n n<\/jats:italic>\n = 262),\n Stenotrophomonas maltophilia<\/jats:named-content>\n (\n n<\/jats:italic>\n = 217), and\n Burkholderia cepacia<\/jats:named-content>\n (\n n<\/jats:italic>\n = 4) using the Clinical and Laboratory Standards Institute (CLSI) standard broth microdilution method. Iron-depleted cation-adjusted Mueller-Hinton broth (ID-CAMHB), prepared according to a recently approved (2017), but not yet published, CLSI protocol, was used to test cefiderocol; all other antimicrobial agents were tested using CAMHB. The concentration of cefiderocol inhibiting 90% (MIC\n 90<\/jats:sub>\n ) of isolates of carbapenem-nonsusceptible\n Enterobacteriaceae<\/jats:named-content>\n was 4 \u03bcg\/ml; cefiderocol MICs ranged from 0.004 to 32 \u03bcg\/ml, and 97.0% (991\/1,022) of isolates demonstrated cefiderocol MICs of \u22644 \u03bcg\/ml. The MIC\n 90<\/jats:sub>\n s for cefiderocol for MDR\n A. baumannii<\/jats:named-content>\n , MDR\n P. aeruginosa<\/jats:named-content>\n , and\n S. maltophilia<\/jats:named-content>\n were 8, 1, and 0.25 \u03bcg\/ml, respectively, with 89.7% (330\/368), 99.2% (260\/262), and 100% (217\/217) of isolates demonstrating cefiderocol MICs of \u22644 \u03bcg\/ml. Cefiderocol MICs for\n B. cepacia<\/jats:named-content>\n ranged from 0.004 to 8 \u03bcg\/ml. We conclude that cefiderocol demonstrated potent\n in vitro<\/jats:italic>\n activity against a 2014\u20132016, worldwide collection of clinical isolates of carbapenem-nonsusceptible\n Enterobacteriaceae<\/jats:named-content>\n , MDR\n A. baumannii<\/jats:named-content>\n , MDR\n P. aeruginosa<\/jats:named-content>\n ,\n S. maltophilia<\/jats:named-content>\n , and\n B. cepacia<\/jats:named-content>\n isolates as 96.2% of all (1,801\/1,873) isolates tested had cefiderocol MICs of \u22644 \u03bcg\/ml.\n <\/jats:p>","DOI":"10.1128\/aac.01968-17","type":"journal-article","created":{"date-parts":[[2017,11,20]],"date-time":"2017-11-20T12:10:20Z","timestamp":1511179820000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":215,"title":["In Vitro<\/i>\n Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016"],"prefix":"10.1128","volume":"62","author":[{"given":"Meredith A.","family":"Hackel","sequence":"first","affiliation":[{"name":"International Health Management Associates, Inc., Schaumburg, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakatsu","family":"Tsuji","sequence":"additional","affiliation":[{"name":"Drug Discovery and Disease Research Laboratory, Shionogi & Co., Ltd., Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Yamano","sequence":"additional","affiliation":[{"name":"Pharmaceutical Research Division, Shionogi & Co., Ltd., Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Echols","sequence":"additional","affiliation":[{"name":"Clinical Development and Medical Affairs, ID3C, LLC, Easton, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Karlowsky","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F.","family":"Sahm","sequence":"additional","affiliation":[{"name":"International Health Management Associates, Inc., Schaumburg, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00107-16"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03042-15"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/jhm.2477"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.3109\/1040841X.2014.940494"},{"key":"e_1_3_2_6_2","volume-title":"CLSI document M100-S27","author":"Clinical and Laboratory Standards Institute","year":"2017","unstructured":"Clinical and Laboratory Standards Institute. 2017. Performance standards for antimicrobial susceptibility testing; twenty-seventh informational supplement. CLSI document M100-S27. CLSI, Wayne, PA."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03938-14"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(10)70004-2"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2006.01456.x"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00019-11"},{"key":"e_1_3_2_11_2","volume-title":"Antimicrobial resistance global report on surveillance","author":"World Health Organization","year":"2014","unstructured":"World Health Organization. 2014. Antimicrobial resistance global report on surveillance. World Health Organization, Geneva, Switzerland. http:\/\/www.who.int\/drugresistance\/documents\/surveillancereport\/en\/."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01405-16"},{"key":"e_1_3_2_13_2","volume-title":"S-649266, a novel siderophore cephalosporin: binding affinity to PBP and bactericidal activity, abstr ECCMID-1871","author":"Ito A","year":"2015","unstructured":"Ito A, Nishikawa T, Oota M, Kanazawa S, Fukuhara N, Yamaguchi T, Nakamura R, Tsuji M, Yamano Y. 2015. S-649266, a novel siderophore cephalosporin: binding affinity to PBP and bactericidal activity, abstr ECCMID-1871. Abstr 25th European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark, 25 to 28 April 2015."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01695-15"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03098-15"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv402"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofu052.118"},{"key":"e_1_3_2_18_2","volume-title":"Subcommittee on Antimicrobial Susceptibility Testing, meeting minutes and presentations, January 2016","author":"Clinical and Laboratory Standards Institute","year":"2016","unstructured":"Clinical and Laboratory Standards Institute. 2016. Subcommittee on Antimicrobial Susceptibility Testing, meeting minutes and presentations, January 2016. CLSI, Wayne, PA."},{"key":"e_1_3_2_19_2","volume-title":"Subcommittee on Antimicrobial Susceptibility Testing, meeting minutes and presentations, January 2017","author":"Clinical and Laboratory Standards Institute","year":"2017","unstructured":"Clinical and Laboratory Standards Institute. 2017. Subcommittee on Antimicrobial Susceptibility Testing, meeting minutes and presentations, January 2017. CLSI, Wayne, PA."},{"key":"e_1_3_2_20_2","volume-title":"Subcommittee on Antimicrobial Susceptibility Testing, meeting minutes and presentations, June 2016","author":"Clinical and Laboratory Standards Institute","year":"2016","unstructured":"Clinical and Laboratory Standards Institute. 2016. Subcommittee on Antimicrobial Susceptibility Testing, meeting minutes and presentations, June 2016. CLSI, Wayne, PA."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.3109\/10408419209114559"},{"key":"e_1_3_2_22_2","volume-title":"S-649266, a novel siderophore cephalosporin: in vivo efficacy in murine infection model caused by multidrug-resistant gram-negative bacteria, abstr 0253","author":"Tsuji M","year":"2015","unstructured":"Tsuji M, Horiyama T, Toba S, Nakamura R, Yamano Y. 2015. S-649266, a novel siderophore cephalosporin: in vivo efficacy in murine infection model caused by multidrug-resistant gram-negative bacteria, abstr 0253. Abstr 25th European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark, 25 to 28 April 2015."},{"key":"e_1_3_2_23_2","volume-title":"Use of iron-depleted cation-adjusted Mueller Hinton broth (ID-CAMHB) for microdilution testing of S-649266, a novel siderophore cephalosporin, abstr 0808","author":"Tsuji M","year":"2015","unstructured":"Tsuji M, Nakamura R, Hackel M, Sahm DF, Sato T, Echols R, Yamano Y. 2015. Use of iron-depleted cation-adjusted Mueller Hinton broth (ID-CAMHB) for microdilution testing of S-649266, a novel siderophore cephalosporin, abstr 0808. Abstr 25th European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark, 25 to 28 April 2015."},{"key":"e_1_3_2_24_2","volume-title":"Abstr ASM Microbe 2016, Boston, MA","author":"Ghazi I","year":"2016","unstructured":"Ghazi I, Tsuji M, Nicolau DP. 2016. Activity of S-649266 siderophore cephalosporin and comparators against Pseudomonas aeruginosa in murine thigh infection model, abstr M-516. Abstr ASM Microbe 2016, Boston, MA, 16 to 20 June 2016. American Society of Microbiology, Washington, DC."},{"key":"e_1_3_2_25_2","volume-title":"Approved standard M07-A10","author":"Clinical and Laboratory Standards Institute","year":"2015","unstructured":"Clinical and Laboratory Standards Institute. 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; tenth edition. Approved standard M07-A10. CLSI, Wayne, PA."},{"key":"e_1_3_2_26_2","volume-title":"S-649266, a novel siderophore cephalosporin: in vitro activity against gram-negative bacteria including carbapenem resistant strains, abstr 0252","author":"Ito A","year":"2015","unstructured":"Ito A, Kohira N, Nakamura R, Tsuji M, Kreiswirth B, Yamano Y. 2015. S-649266, a novel siderophore cephalosporin: in vitro activity against gram-negative bacteria including carbapenem resistant strains, abstr 0252. Abstr 25th European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark, 25 to 28 April 2015."},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx049"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00093-17"},{"key":"e_1_3_2_29_2","article-title":"In-vitro activity of cefiderocol (S-649266) against multidrug-resistant Enterobacteriaceae from the UK, abstr P1315","author":"Mushtaq S","year":"2017","unstructured":"Mushtaq S, Vickers A, Hussain A, Livermore D, Woodford N. 2017. In-vitro activity of cefiderocol (S-649266) against multidrug-resistant Enterobacteriaceae from the UK, abstr P1315. Abstr 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, 22 to 25 April 2017.","journal-title":"Abstr 27th European Congress of Clinical Microbiology and Infectious Diseases"},{"key":"e_1_3_2_30_2","volume-title":"Activity of the novel siderophore cephalosporin cefiderocol (S-649266) against Gram-negative pathogens, abstr OS0561","author":"Dobias J","year":"2017","unstructured":"Dobias J, Denervaud V, Poirel L, Nordmann P. 2017. Activity of the novel siderophore cephalosporin cefiderocol (S-649266) against Gram-negative pathogens, abstr OS0561. Abstr 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, 22 to 25 April 2017."},{"key":"e_1_3_2_31_2","volume-title":"Mode of action of cefiderocol, a novel siderophore cephalosporin, active against highly resistant Gram-negative bacteria including carbapenem-resistant strains of Enterobacteriaceae and non-fermenting bacteria, abstr OS0750","author":"Yamano Y","year":"2017","unstructured":"Yamano Y, Tsuji M, Hackel M, Sahm D, Echols R. 2017. Mode of action of cefiderocol, a novel siderophore cephalosporin, active against highly resistant Gram-negative bacteria including carbapenem-resistant strains of Enterobacteriaceae and non-fermenting bacteria, abstr OS0750. Abstr 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, 22 to 25 April 2017."},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03570.x"},{"key":"e_1_3_2_33_2","volume-title":"Abstr ASM Microbe 2016, Boston, MA","author":"Tsuji M","year":"2016","unstructured":"Tsuji M, Hackel M, Echols R, Sahm D, Yamano Y. 2016. MIC reproducibility of iron depleted cation adjusted-Mueller Hinton broth (ID-CAMHB) for microdilution testing of S-649266, a novel siderophore cephalosporin, abstr M-470. Abstr ASM Microbe 2016, Boston, MA, 16 to 20 June 2016. American Society of Microbiology, Washington, DC."},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01381-16"},{"key":"e_1_3_2_35_2","volume-title":"S-649266, a novel siderophore cephalosporin: efficacy against Klebsiella pneumoniae producing NDM-1 or KPC in rat lung infection model with recreated humanized exposure profile of 2 g dose with 1 or 3 h infusion, abstr 248","author":"Tsuji M","year":"2014","unstructured":"Tsuji M, Horyama T, Nakamura R, Echols R, Singley C, Rittenhouse S, Yamano Y. 2014. S-649266, a novel siderophore cephalosporin: efficacy against Klebsiella pneumoniae producing NDM-1 or KPC in rat lung infection model with recreated humanized exposure profile of 2 g dose with 1 or 3 h infusion, abstr 248. Abstr IDWeek 2014, Philadelphia, PA, 8 to 12 October 2014."},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01022-17"},{"key":"e_1_3_2_37_2","volume-title":"Avycaz package insert","author":"Allergan Plc","year":"2015","unstructured":"Allergan Plc. 2015. Avycaz package insert. Allergan, Plc, Dublin, Ireland. https:\/\/www.allergan.com\/assets\/pdf\/avycaz_pi."},{"key":"e_1_3_2_38_2","volume-title":"Breakpoint tables for interpretation of MICs and zone diameters, version 7.0, valid from 2017-01-01","author":"European Committee on Antimicrobial Susceptibility Testing","year":"2017","unstructured":"European Committee on Antimicrobial Susceptibility Testing. 2017. Breakpoint tables for interpretation of MICs and zone diameters, version 7.0, valid from 2017-01-01. European Committee on Antimicrobial Susceptibility Testing, Copenhagen Denmark. http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_7.0_Breakpoint_Tables.pdf."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01968-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01968-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T16:10:35Z","timestamp":1645459835000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01968-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1128\/AAC.01968-17"],"URL":"https:\/\/doi.org\/10.1128\/aac.01968-17","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732142063.793555386","asserted-by":"object"}]},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"2017-09-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-11-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-01-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01968-17"}}